IL-17A in COVID-19 Cases: A meta-analysis

dc.contributor.authorFadlallah, Sukayna M.
dc.contributor.authorSham Eddin, Marcel S.
dc.contributor.authorRahal, Elias A.
dc.contributor.departmentExperimental Pathology, Microbiology, and Immunology
dc.contributor.departmentSpecialized Clinical Programs and Services
dc.contributor.departmentCenter for Infectious Diseases Research
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T11:39:07Z
dc.date.available2025-01-24T11:39:07Z
dc.date.issued2021
dc.description.abstractIntroduction: Numerous reviews, commentaries and opinion pieces have suggested targeting IL-17A as part of managing Coronavirus disease 2019 (COVID-19), the notorious pandemic caused by the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). IL-17A is a proinflammatory cytokine attributed with homeostatic roles but that is also involved in autoimmune disease pathogenesis. While some studies have reported an increase in IL-17A in COVID-19 cases, no significant associations were found by others. Hence, we undertook this meta-analysis to study serum IL-17A levels in COVID-19 patients in relation to disease severity. Methodology: Multiple databases were systematically reviewed for literature published on the topic from January 1, 2019 to April 30, 2021. A random effects model was used to calculate weighted mean differences (WMDs) and 95% confidence interval (CIs) as well as the τ2 and I2 statistics for heterogeneity analysis. Results: We report that IL-17A increases in COVID-19 subjects irrespective of disease severity compared to controls [WMD = 2.51 pg/ml (95% CI 1.73-3.28), p < 0.00001]. It is also higher in patients with moderate disease compared to controls [WMD = 2.41 pg/ml (95% CI:1.40-3.43), p < 0.00001] as well as higher in patients with severe COVID-19 [WMD = 4.13 pg/ml (95% CI:1.65-6.60), p = 0.001]. While the increase in serum levels in subjects with severe disease over those with moderate disease was statistically significant, the association was not as robust as the other comparisons [WMD = 2.07 pg/ml (95% CI:0.20-3.95), p = 0.03]. Variable heterogeneity was observed in the various analyses with no significant publication bias detected. Conclusions: Hence, IL-17A may be of relevance when considering management approaches to COVID-19. Copyright © 2021 Fadlallah et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
dc.identifier.doihttps://doi.org/10.3855/JIDC.15285
dc.identifier.eid2-s2.0-85122132876
dc.identifier.pmid34898490
dc.identifier.urihttp://hdl.handle.net/10938/29181
dc.language.isoen
dc.publisherJournal of Infection in Developing Countries
dc.relation.ispartofJournal of Infection in Developing Countries
dc.sourceScopus
dc.subjectCovid-19
dc.subjectIl-17a
dc.subjectSars-cov-2
dc.subjectGlobal health
dc.subjectHumans
dc.subjectInterleukin-17
dc.subjectPandemics
dc.subjectInterleukin 17
dc.subjectIl17a protein, human
dc.subjectArticle
dc.subjectBlood sampling
dc.subjectClinical outcome
dc.subjectCoronavirus disease 2019
dc.subjectDisease severity
dc.subjectHospital admission
dc.subjectHuman
dc.subjectImmune response
dc.subjectMeta analysis
dc.subjectSevere acute respiratory syndrome coronavirus 2
dc.subjectSystematic review
dc.subjectTh17 cell
dc.subjectBlood
dc.subjectPandemic
dc.titleIL-17A in COVID-19 Cases: A meta-analysis
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021-5822.pdf
Size:
2.57 MB
Format:
Adobe Portable Document Format